Review




Structured Review

CEM Corporation human leukemia carcinoma ccrf-cem cell line
In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) human leukemia carcinoma (CCRF-CEM), ( b ) human ovarian <t>adenocarcinoma</t> (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.
Human Leukemia Carcinoma Ccrf Cem Cell Line, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leukemia carcinoma ccrf-cem cell line/product/CEM Corporation
Average 90 stars, based on 1 article reviews
human leukemia carcinoma ccrf-cem cell line - by Bioz Stars, 2026-03
90/100 stars

Images

1) Product Images from "Design, Synthesis, and Antiproliferative Activity of Benzopyran-4-One-Isoxazole Hybrid Compounds"

Article Title: Design, Synthesis, and Antiproliferative Activity of Benzopyran-4-One-Isoxazole Hybrid Compounds

Journal: Molecules

doi: 10.3390/molecules28104220

In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) human leukemia carcinoma (CCRF-CEM), ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.
Figure Legend Snippet: In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) human leukemia carcinoma (CCRF-CEM), ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.

Techniques Used: In Vitro, Concentration Assay, Control



Similar Products

96
ATCC human leukemia carcinoma cell line
Human Leukemia Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leukemia carcinoma cell line/product/ATCC
Average 96 stars, based on 1 article reviews
human leukemia carcinoma cell line - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

90
CEM Corporation human leukemia carcinoma ccrf-cem cell line
In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) human leukemia carcinoma (CCRF-CEM), ( b ) human ovarian <t>adenocarcinoma</t> (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.
Human Leukemia Carcinoma Ccrf Cem Cell Line, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leukemia carcinoma ccrf-cem cell line/product/CEM Corporation
Average 90 stars, based on 1 article reviews
human leukemia carcinoma ccrf-cem cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
CEM Corporation human leukemia carcinoma cell lines
In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) <t>human</t> <t>leukemia</t> carcinoma <t>(CCRF-CEM),</t> ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.
Human Leukemia Carcinoma Cell Lines, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leukemia carcinoma cell lines/product/CEM Corporation
Average 90 stars, based on 1 article reviews
human leukemia carcinoma cell lines - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
CEM Corporation human leukemia carcinoma cell line (ccrf-cem)
In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) <t>human</t> <t>leukemia</t> carcinoma <t>(CCRF-CEM),</t> ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.
Human Leukemia Carcinoma Cell Line (Ccrf Cem), supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leukemia carcinoma cell line (ccrf-cem)/product/CEM Corporation
Average 90 stars, based on 1 article reviews
human leukemia carcinoma cell line (ccrf-cem) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
CEM Corporation human leukemia carcinoma cell line
In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) <t>human</t> <t>leukemia</t> carcinoma <t>(CCRF-CEM),</t> ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.
Human Leukemia Carcinoma Cell Line, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leukemia carcinoma cell line/product/CEM Corporation
Average 90 stars, based on 1 article reviews
human leukemia carcinoma cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

96
ATCC human leukemia carcinoma cell line ccrf cem
In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) <t>human</t> <t>leukemia</t> carcinoma <t>(CCRF-CEM),</t> ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.
Human Leukemia Carcinoma Cell Line Ccrf Cem, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leukemia carcinoma cell line ccrf cem/product/ATCC
Average 96 stars, based on 1 article reviews
human leukemia carcinoma cell line ccrf cem - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

96
ATCC human leukemia carcinoma cell line ccrfcem
In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) <t>human</t> <t>leukemia</t> carcinoma <t>(CCRF-CEM),</t> ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.
Human Leukemia Carcinoma Cell Line Ccrfcem, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leukemia carcinoma cell line ccrfcem/product/ATCC
Average 96 stars, based on 1 article reviews
human leukemia carcinoma cell line ccrfcem - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

96
ATCC cell culture human leukemia carcinoma cell line ccrf cem
In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) <t>human</t> <t>leukemia</t> carcinoma <t>(CCRF-CEM),</t> ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.
Cell Culture Human Leukemia Carcinoma Cell Line Ccrf Cem, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell culture human leukemia carcinoma cell line ccrf cem/product/ATCC
Average 96 stars, based on 1 article reviews
cell culture human leukemia carcinoma cell line ccrf cem - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

Image Search Results


In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) human leukemia carcinoma (CCRF-CEM), ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.

Journal: Molecules

Article Title: Design, Synthesis, and Antiproliferative Activity of Benzopyran-4-One-Isoxazole Hybrid Compounds

doi: 10.3390/molecules28104220

Figure Lengend Snippet: In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) human leukemia carcinoma (CCRF-CEM), ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.

Article Snippet: This panel involved human leukemia carcinoma (CCRF-CEM), human ovarian adenocarcinoma (SKOV-3), human breast tumor (MDA-MB-231), human prostate cancer (PC-3), androgen-independent human prostate cancer (DU-145), and human renal carcinoma (iSLK) cell lines.

Techniques: In Vitro, Concentration Assay, Control

In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) human leukemia carcinoma (CCRF-CEM), ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.

Journal: Molecules

Article Title: Design, Synthesis, and Antiproliferative Activity of Benzopyran-4-One-Isoxazole Hybrid Compounds

doi: 10.3390/molecules28104220

Figure Lengend Snippet: In vitro cytotoxicity of benzopyran-4-one-isoxazole conjugates (at a concentration of 25 μM) towards ( a ) human leukemia carcinoma (CCRF-CEM), ( b ) human ovarian adenocarcinoma (SKOV-3), ( c ) human breast tumor (MDA-MB-231), ( d ) human prostate cancer (PC-3), ( e ) androgen-independent human prostate cancer (DU-145), and ( f ) human renal carcinoma (iSLK) cell lines using DMSO and standard anticancer drug doxorubicin (Dox) (at a concentration of 5 μM) as controls after 24 and 72 h. The results are shown as the percentage of control that has no compound (set at 100%). All the experiments were performed in triplicate.

Article Snippet: The in vitro cytotoxicity of the conjugates was evaluated using six human cancer cell lines, one human normal kidney cell line, and one mammalian normal kidney cell line, which included human leukemia carcinoma cell lines (CCRF-CEM), human ovarian adenocarcinoma cell lines (SKOV-3), human breast tumor cell lines (MDA-MB-231), human prostate cancer cell lines (PC-3), androgen-independent human prostate cancer cell lines (DU-145), human renal carcinoma (iSLK), human embryonic kidney cell lines (HEK-293), and normal mammalian kidney cell line (LLCPK) to determine the toxicity of the synthesized conjugates.

Techniques: In Vitro, Concentration Assay, Control

IC 50 (μM) of selected compounds 5a – d against  human leukemia carcinoma (CCRF-CEM), human  breast cancer (MDA-MB-231), human prostate cancer (PC-3), androgen-independent human prostate cancer (DU-145), and human embryonic kidney (HEK-293) cell lines.

Journal: Molecules

Article Title: Design, Synthesis, and Antiproliferative Activity of Benzopyran-4-One-Isoxazole Hybrid Compounds

doi: 10.3390/molecules28104220

Figure Lengend Snippet: IC 50 (μM) of selected compounds 5a – d against human leukemia carcinoma (CCRF-CEM), human breast cancer (MDA-MB-231), human prostate cancer (PC-3), androgen-independent human prostate cancer (DU-145), and human embryonic kidney (HEK-293) cell lines.

Article Snippet: The in vitro cytotoxicity of the conjugates was evaluated using six human cancer cell lines, one human normal kidney cell line, and one mammalian normal kidney cell line, which included human leukemia carcinoma cell lines (CCRF-CEM), human ovarian adenocarcinoma cell lines (SKOV-3), human breast tumor cell lines (MDA-MB-231), human prostate cancer cell lines (PC-3), androgen-independent human prostate cancer cell lines (DU-145), human renal carcinoma (iSLK), human embryonic kidney cell lines (HEK-293), and normal mammalian kidney cell line (LLCPK) to determine the toxicity of the synthesized conjugates.

Techniques: